Tema ETFs LLC Reduces Holdings in BridgeBio Pharma, Inc. $BBIO

Tema ETFs LLC reduced its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 32.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 76,076 shares of the company’s stock after selling 36,197 shares during the quarter. Tema ETFs LLC’s holdings in BridgeBio Pharma were worth $5,666,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its holdings in shares of BridgeBio Pharma by 19.8% during the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock worth $978,608,000 after buying an additional 2,178,556 shares in the last quarter. Farallon Capital Management LLC lifted its stake in shares of BridgeBio Pharma by 9.8% in the fourth quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock worth $688,292,000 after buying an additional 806,463 shares in the last quarter. Invesco Ltd. boosted its position in BridgeBio Pharma by 23.0% during the fourth quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock worth $369,547,000 after acquiring an additional 902,648 shares during the last quarter. Geode Capital Management LLC boosted its position in BridgeBio Pharma by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 4,412,523 shares of the company’s stock worth $344,689,000 after acquiring an additional 502,582 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in BridgeBio Pharma by 144.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock worth $292,862,000 after acquiring an additional 2,261,181 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong commercial growth: Second-quarter revenue rose 120.4% year over year to $243.68 million, exceeding the $220.91 million consensus estimate. Attruby U.S. net sales reportedly increased 311% year over year, while ex-U.S. Beyonttra royalties rose 62% sequentially. BridgeBio reaffirmed guidance for more than $1 billion in combined 2026 Attruby and Beyonttra global sales and expects three product launches by mid-2027. BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
• Positive Sentiment: Analyst optimism increased: Piper Sandler raised its price target to $115, TD Cowen to $110, Bank of America to $104 and Wells Fargo to $102; all maintained positive ratings. Morgan Stanley trimmed its target slightly to $97 but retained an Overweight rating. These targets imply substantial upside from recent trading levels. Analyst price target updates
• Positive Sentiment: Pipeline catalysts remain in focus: BridgeBio is among biotechnology companies expected to have potentially important second-half 2026 clinical or regulatory catalysts, which may support investor interest in the shares. Four Biotech Stocks With Major Second-Half Pipeline Catalysts
• Neutral Sentiment: Limited short-interest signal: Reported short interest was zero shares as of August 11, unchanged from the prior period, so short covering is unlikely to be a meaningful driver of the current move.
• Neutral Sentiment: BridgeBio granted restricted stock units covering 66,705 shares to 56 new employees under Nasdaq’s inducement-grant exception. The grants support hiring but could result in modest future dilution. BridgeBio Pharma Reports Inducement Grants
• Negative Sentiment: Quarterly loss missed expectations: BBIO reported a loss of $0.78 per share, wider than the $0.58 consensus estimate, although the loss improved from $0.95 per share a year earlier. The earnings shortfall likely outweighed the revenue beat in near-term trading. BridgeBio Pharma Q2 Earnings Results

BridgeBio Pharma Price Performance

BridgeBio Pharma stock opened at $83.70 on Wednesday. The firm has a 50 day simple moving average of $76.47 and a 200-day simple moving average of $73.07. The stock has a market cap of $16.36 billion, a price-to-earnings ratio of -23.45 and a beta of 0.96. BridgeBio Pharma, Inc. has a 1-year low of $46.81 and a 1-year high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The company had revenue of $243.68 million during the quarter, compared to analysts’ expectations of $220.91 million. The business’s revenue was up 120.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.95) EPS. Equities analysts expect that BridgeBio Pharma, Inc. will post -2.31 earnings per share for the current fiscal year.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, CEO Neil Kumar sold 40,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $67.46, for a total value of $2,698,400.00. Following the transaction, the chief executive officer owned 535,686 shares of the company’s stock, valued at $36,137,377.56. This represents a 6.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Randal W. Scott sold 10,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $67.15, for a total transaction of $671,500.00. Following the transaction, the director directly owned 11,589 shares of the company’s stock, valued at approximately $778,201.35. This trade represents a 46.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 392,117 shares of company stock worth $29,934,700. Insiders own 14.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on BBIO. Wells Fargo & Company increased their price objective on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the company an “overweight” rating in a report on Tuesday. Morgan Stanley lowered their target price on BridgeBio Pharma from $98.00 to $97.00 and set an “overweight” rating on the stock in a report on Tuesday. TD Cowen upped their price target on BridgeBio Pharma from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $110.00 price target on shares of BridgeBio Pharma in a report on Tuesday. Finally, Bank of America lifted their price objective on BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday. Twenty analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.53.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.